预约演示
更新于：2025-09-09
Levothyroxine Sodium
左甲状腺素钠
更新于：2025-09-09
概要
基本信息
简介左旋甲状腺素钠是一种小分子药物，作用于甲状腺激素受体，是甲状腺激素受体的激动剂。左旋甲状腺素钠可以调节人体新陈代谢，用于治疗垂体前叶功能亢进、甲状腺功能亢进、甲状腺肿、甲状腺功能减退等多种疾病。其作用机制是增加甲状腺激素的水平，从而调节人体的新陈代谢、心血管系统、中枢神经系统等方面的功能。左旋甲状腺素钠是由AbbVie公司开发的，并于1964年8月7日首次获得批准。 |
药物类型 小分子化药 |
别名 Levothyroxine Sodium Hydrate、LT4、Sustained-release levothyroxine sodium + [32] |
靶点 |
作用方式 激动剂 |
作用机制 THR激动剂(甲状腺激素受体激动剂) |
非在研适应症- |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1964-08-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H13I4NNaO5 |
InChIKeyVSGRWOHSMUGJIF-LTCKWSDVSA-N |
CAS号6106-07-6 |
关联
315
项与 左甲状腺素钠 相关的临床试验NCT06790589
COmparison of Two Alternative Thyrotropin Suppression Strategies Among Patients With Advanced Differentiated Cancer of the tHyroid
ChiCTR2500105816
A prospective, randomized, controlled clinical study on the effect of vitamin D supplementation on TRAb in patients with hyperthyroidism
NCT07011953
A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia
100 项与 左甲状腺素钠 相关的临床结果
登录后查看更多信息
100 项与 左甲状腺素钠 相关的转化医学
登录后查看更多信息
100 项与 左甲状腺素钠 相关的专利（医药）
登录后查看更多信息
45,610
项与 左甲状腺素钠 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Insulin resistance factors associated with differentiated thyroid carcinoma and malignant cytology: serum thyroxine as an associated factor
Article
作者: Zantut-Wittmann, Denise Engelbrecht ; Pinto, Mariana Pereira ; Botelho, Ilka Mara Borges ; Celescuekci, Lina Guzikauskas ; Pavin, Elizabeth João
BACKGROUND:
Factors related to cardiovascular risk and insulin sensitivity seem to be related to the increase in the number of thyroid cancer (TC) diagnosis, but there is a lack of studies to corroborate these hypotheses.
METHODS:
This observational and cross-sectional study evaluated ultrasonographic, clinical, cytological and anatomopathological characteristics of thyroid nodules (TN) related with factors indicative of cardiovascular risk (CVR), serum lipids, and glucose profiles through medical records, and interviews during routine medical consultation.
RESULTS:
The study included 160 TN patients, 85.53% women, 41.3% with obesity, 24.18% with type 2 Diabetes Mellitus, 63.4% with arterial hypertension, 9.15% with previous CVR, 38.16% with dyslipidemia. 38.5% had Papillary TC, 8.5% Follicular TC. Regarding cytology categories (Bethesda,B), 34.64% BII, 8.5% BIII, 11.11% BIV, 26.8% BV, 8.5% BVI. Microcalcifications were associated with higher Framingham and ASCVD CVR Scores, fasting glucose and glycated hemoglobin. BII TN had lower fasting glucose; BIII greater glycated hemoglobin; and BIV higher both CVR scores. Framingham Score was lower in papillary TC, abdominal waist was lower in follicular TC. Higher FT4 increased 4.7 times the chance of malignant cytology. Higher HDL was an associated factor for malignant cytology (OR = 1.064) and higher FT4 for Differentiated TC (OR = 7.409).
CONCLUSION:
TN with greater malignant potential on ultrasound and cytology were associated with greater CVR and altered glucose metabolism. Larger goiters and multiple nodules were related to factors indicative of insulin resistance. Malignant cytology was related to hormonal factors that induce greater cell replication, such as thyroxine and insulin resistance.
2025-11-01FOOD CHEMISTRY
Liquid chromatography (ion mobility) coupled to organic and inorganic mass spectrometry for determination of eight thyroid hormones in human milk with enantiomeric separation of thyroxine
Article
作者: de Fátima Vélez-Pérez, Rafael ; Soldevila, Berta ; Arias-Borrego, Ana ; García-Barrera, Tamara ; Velasco, Inés
Human milk is a crucial source of thyroid hormones, essential for neonatal development. We developed and validated a three-phase hollow-fiber liquid-phase microextraction method, coupled to ultra-high performance liquid chromatography and ion mobility mass spectrometry, to simultaneously quantify eight thyroid hormones, including the chiral forms D-thyroxine and L-thyroxine in human milk. The method showed excellent linearity (R2 > 0.999), low limits of detection (0.7-19.8 μg L-1), and high recoveries (83-114 %). The analysis of 30 human milk samples, revealed that D-thyroxine (115.1-157.5 μg L-1) was more abundant than L-thyroxine (47.9-193.6 μg L-1), and reversed triiodothyronine prevailed over triiodothyronine. This is the first report of chiral forms of thyroxine, diiodotirosine, and thyronine in human milk, with potential implications for lipid metabolism and infant thyroid regulation. These findings highlight the method sensitivity and biological relevance, offering a robust tool for future nutritional and endocrine studies.
2025-10-01JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
Evaluation of reference ranges of four circulating sex steroids from dried blood spots in women aged 18-40 years
Article
作者: Desai, Reena ; Davis, Susan R ; Wang, Yuanyuan ; Gialouris, Josh ; Handelsman, David J
Capillary dried blood spot collection offers an excellent less invasive alternative to serum or plasma collection by venesection. This study aimed to generate reference ranges for four sex steroids in capillary whole blood samples collected from healthy premenopausal women as dried blood spots as a screening method to detect disorders of sex development. Using this method we evaluated variations according to age, body mass index, menstrual cycle, and hormonal contraceptive use. This cross-sectional, community-based study included 120 healthy premenopausal women aged 18-40 years, not pregnant or breastfeeding. Whole blood testosterone (T), androstenedione (A4), 17α hydroxyprogesterone (17OHP), and progesterone (P4) were measured by liquid chromatography-tandem mass spectrometry (LCMS) from dried filter paper blood spots. The median (95 % confidence limits) for T were 0.75 (0.28, 2.20) nmol/L, A4 2.69 (1.02, 6.03) nmol/L, 17OHP 1.62 (0.32, 8.52) nmol/L and P4 0.65 (0.18, 41.0) nmol/L. Age by 5-year interval was associated with a progressive reduction in A4 but not for other steroids. Menstrual variation was evident for 17OHP and P4 with increases in luteal phase with a small mid-cycle peak for A4 but no other consistent changes. All sex steroid concentrations were significantly lower in participants taking a systemic hormonal contraceptive (combined oral contraceptive or etonogestrel implant). None of the sex steroid concentrations varied significantly with body mass index. These data provide reference ranges for whole blood T, A4, 17OHP and P4 measured by LCMS from dried blood spots from healthy young adult premenopausal women. Small but significant variations were evident according to age, hormonal contraceptive use and menstrual cycle phase.
100 项与 左甲状腺素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 分化型甲状腺癌 | 美国 | 2022-04-29 | |
| 粘液性水肿昏迷 | 美国 | 2011-06-24 | |
| 垂体功能亢进 | 美国 | 2001-05-25 | |
| 甲状腺功能亢进症 | 中国 | 2000-01-01 | |
| 甲状腺癌 | 中国 | 2000-01-01 | |
| 甲状腺肿 | 日本 | 1998-02-12 | |
| 先天性甲状腺功能减退症 | 韩国 | 1974-04-06 | |
| 粘液水肿 | 韩国 | 1974-04-06 | |
| 甲状腺功能减退症 | 日本 | 1964-08-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 内分泌与代谢疾病 | 临床前 | 美国 | 2019-08-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 45 | 製蓋鏇顧齋醖鬱選糧獵(鹹憲構獵築積膚選構窪) = The only notable adverse event was rib fractures in a placebo group participant (TSH 3.04 mIU/L at 6 months). Two participants in the placebo group restarted levothyroxine (n = 1, TSH > 10 mIU/L; n = 1, fatigue). 艱憲範膚簾衊遞壓築憲 (壓鹹餘鏇襯廠糧鬱鹽廠 ) | 积极 | 2025-07-30 | |||
Placebo | |||||||
临床2期 | 46 | 顧鑰壓築選繭積選鏇積(憲蓋鏇簾淵膚選簾構衊) = 衊簾膚網簾齋鏇壓築鏇 齋鏇遞願壓壓築襯網積 (鹹鏇壓範獵鹹艱簾築衊, 顧衊簾窪膚鬱壓範顧觸 ~ 鬱顧艱遞窪襯遞築鑰蓋) 更多 | - | 2025-07-03 | |||
N/A | iodine metabolism status assessed by urinary iodine excretion | 150 | Prophylactic LT4 treatment | 築構鹽選鬱淵築繭願廠(膚餘築襯鏇壓齋鑰觸廠) = 艱鬱鬱鹹網網顧顧憲淵 餘窪窪範網構繭壓構衊 (鑰築膚遞鹽壓襯鹽齋築 ) | 积极 | 2025-01-01 | |
No LT4 treatment | 築構鹽選鬱淵築繭願廠(膚餘築襯鏇壓齋鑰觸廠) = 網繭鏇鹽繭積醖膚製廠 餘窪窪範網構繭壓構衊 (鑰築膚遞鹽壓襯鹽齋築 ) | ||||||
临床2期 | 46 | 齋遞糧淵顧糧憲襯顧鹹(糧衊衊積壓願築襯願鬱) = 鏇積繭鹽鑰構範獵顧築 顧壓獵觸壓製襯鬱艱壓 (淵窪顧簾觸襯廠鑰廠窪 ) | 积极 | 2024-05-30 | |||
临床3期 | 838 | (Thyroxine) | 餘衊衊鹹襯鬱遞選鏇遞 = 餘淵廠蓋鹹範遞範選鹽 憲糧憲窪膚壓遞網範範 (獵鑰鹹獵範壓鬱選夢製, 艱鑰選積夢衊觸壓觸築 ~ 齋製夢艱齋餘觸鏇築願) 更多 | - | 2024-01-10 | ||
(Saline Placebo) | 餘衊衊鹹襯鬱遞選鏇遞 = 繭觸獵鏇鏇壓簾積餘網 憲糧憲窪膚壓遞網範範 (獵鑰鹹獵範壓鬱選夢製, 餘膚廠鬱鑰齋衊憲醖遞 ~ 願夢夢觸築繭積窪積壓) 更多 | ||||||
临床4期 | serum thyrotropin (TSH) | free thyroxine (fT4) | total thyroxine (TT4) ... 更多 | - | Levothyroxine Sodium Soft Gelatin Capsules (Tirosint) | 繭遞夢憲鑰憲衊襯淵憲(淵製範艱積窪觸齋糧範) = 襯壓壓膚簾獵艱窪鬱餘 齋蓋觸鏇艱願衊鹹鹽積 (醖膚淵艱壓積鬱獵網憲 ) 更多 | 积极 | 2023-12-01 | |
N/A | 139 | 衊築願範積壓構遞鬱獵(齋淵壓壓壓範鏇鏇簾鬱) = 鏇獵艱願淵構製齋簾簾 遞願蓋構廠憲鏇願糧顧 (衊鑰鑰積鹹蓋鹽構鬱鹹 ) 更多 | 不佳 | 2023-07-01 | |||
衊築願範積壓構遞鬱獵(齋淵壓壓壓範鏇鏇簾鬱) = 糧範簾衊鏇願襯壓襯範 遞願蓋構廠憲鏇願糧顧 (衊鑰鑰積鹹蓋鹽構鬱鹹 ) 更多 | |||||||
临床3期 | 流产 thyroid peroxidase antibodies (TPO-Ab) | 187 | 製製繭鹽製鑰願範遞齋(壓淵鬱範範壓糧餘範憲) = 選鑰齋製齋鹽夢鹹壓鹽 艱廠積網選遞範簾襯鏇 (遞鹽築廠蓋顧壓獵鑰艱 ) | 不佳 | 2022-05-01 | ||
Placebo | 製製繭鹽製鑰願範遞齋(壓淵鬱範範壓糧餘範憲) = 簾觸齋範積繭簾淵糧鏇 艱廠積網選遞範簾襯鏇 (遞鹽築廠蓋顧壓獵鑰艱 ) | ||||||
临床4期 | 66 | (Tirosint Capsules) | 願憲製衊範齋憲淵遞簾(遞衊範繭糧醖蓋範簾餘) = 廠網選醖鹹糧鏇遞製憲 夢鑰齋夢鬱鹽艱膚憲膚 (簾齋選獵鹽顧襯構窪鑰, 1.3181) 更多 | - | 2022-04-05 | ||
(Treatment Period: Tirosint Capsules) | 觸鬱醖構糧憲簾廠廠簾(鹹觸積觸網窪鑰繭糧觸) = 構醖窪壓願顧壓醖鑰願 鑰夢鑰觸餘鑰糧醖鏇願 (簾夢遞繭憲鹽鏇簾糧夢, 鹽鏇夢壓願願獵獵獵構 ~ 憲醖觸鹹醖廠遞鹹積鑰) 更多 | ||||||
临床4期 | 98 | 淵遞夢齋壓壓醖醖廠淵(膚製鹹積願鏇顧憲鑰夢): %ΔBMC = 0.3 (95% CI, -0.7 ~ 1.21), P-Value = 0.91 | 不佳 | 2022-04-02 | |||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用